Baird initiates Kardigan stock with Outperform rating, $43 target By Investing.com

Baird has initiated coverage on Kardigan Inc (NASDAQ: KARD) with an Outperform rating and a $43.00 price target, citing the company's precision-cardiology portfolio, especially danicamtiv's potential for improving heart function. Analysts maintain a Strong Buy consensus, with price targets ranging from $25 to $46. The company, a clinical-stage biotech, holds more cash than debt and expects Phase 2 readouts across its three programs in the first half of 2027, which could drive significant share-price appreciation.